Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.57 |
| ▸ | INSR | P06213 | 1/20 | 0.53 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | ROS1 | P08922 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.52 |
| ▸ | FER | P16591 | 1/20 | 0.52 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.52 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.52 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.52 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27076053 | 0.94 | EGFR (0.64) | EGFRINSRIGF1RALKCHEK1 | |
| SCHEMBL27076000 | 0.91 | EGFR (0.68) | EGFRINSRIGF1RALK | |
| SCHEMBL27075986 | 0.89 | EGFR (0.62) | EGFRALKPLK1 | |
| SCHEMBL29785289 | 0.88 | EGFR (0.69) | EGFR | |
| SCHEMBL27091451 | 0.88 | EGFR (0.69) | EGFR | |
| SCHEMBL27076089 | 0.86 | EGFR (0.65) | EGFRINSRIGF1RALK | |
| SCHEMBL27076058 | 0.86 | ALK (0.72) | EGFRINSRIGF1RALKCHEK1 | |
| SCHEMBL30936774 | 0.85 | EGFR (0.69) | EGFRINSRIGF1RALKMET | |
| SCHEMBL26906941 | 0.84 | EGFR (0.60) | EGFRCHEK1AURKACCNT1JAK2 | |
| SCHEMBL29785287 | 0.83 | EGFR (0.78) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297194-B2 | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | Bridge Biotherapeutics, Inc. (KR) | 2025-05-13 | — | — | US | disclosed |
| EP-4313969-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | Bridge Biotherapeutics, Inc. (KR) | 2024-02-07 | — | — | EP | disclosed |
| CN-117203199-A | N2-phenylpyrimidine-2, 4-diamine compounds, methods of making and using the same | 毕利吉生物科技股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20220332711-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | Bridge Biotherapeutics, Inc. (KR) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297194-B2 | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | EGFR, ERBB2, ERBB4 | EGFR 1/4885INSR 1593/4885IGF1R 369/4885 |
| US-20220332711-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885INSR 1593/4885IGF1R 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.